Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BETABAT

Financiado

Cerrado

Development of novel treatment strategies based on knowledge of cellular dysfunc...

Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in the context of obesity and insulin resistance. Brown adipose tissue (BAT) is a highly metabo... ver más

30/09/2015

ULB

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITE LIBRE DE BRUXELLES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-09-30 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

ULB

0.00€ | Lider

N.D. | Participante

VTT

N.D. | Participante

MHH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MITIN INTEGRATION OF THE SYSTEM MODELS OF INSULIN SIGNALLING AND O... 4M€ Cerrado

ExoDia Cross talk between skeletal muscle and pancreatic islets im... 185K€ Cerrado

SAF2010-21792 EL DIMORFISMO SEXUAL EN LA FUNCION MITOCONDRIAL DEL TEJIDO A... 97K€ Cerrado

Multi-Islet Development of Multiscale Analysis of Pancreatic Beta Cell F... 200K€ Cerrado

BETA-JUDO Beta cell function in juvenile diabetes and obesity 8M€ Cerrado

HuPIPA A Human Pancreatic Islet Perturbation Atlas (HuPIPA) to deci... 165K€ Cerrado

Líder del proyecto

UNIVERSITE LIBRE DE BRUXELLES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in the context of obesity and insulin resistance. Brown adipose tissue (BAT) is a highly metabolic organ, mediating energy dissipation and glucose disposal, thus contributing to maintain energy balance. BAT dysfunction contributes to obesity and impaired glucose metabolism, increasing functional demand on the beta cells. The cellular dysfunction of beta cells and BAT in diabetes is the fruit of defective signal transduction and organelle function, and the vulnerability to these molecular defects may be modulated by diabetes genes. To identify the crosstalk and pathways responsible for beta cell and BAT dysfunction and beta cell apoptosis in diabetes at its real level of complexity, this consortium will use cutting edge genetics, functional (epi)genomics, molecular biology and computational tools to reach an accurate organelle and cell diagnosis. This diagnosis will be used to define novel targets for intervention to prevent dysfunction and facilitate recovery of functionally impaired metabolic tissues. Some of these targets have already been identified by consortium members, including endoplasmic reticulum (ER) stress and mitochondrial dysfunction and apoptosis. Since many of these targets are related to dysfunction of specific organelles, we will focus on the novel concept of organelle therapy, aiming to preserve mitochondrial and ER function by the use of viral vectors and small molecule chemical probes. We will thus follow a two-pronged approach, namely a focused approach to restore known and specific cellular/organelle dysfunctions and a systems biology approach to identify novel targets for intervention. This, in combination with high throughput screening of large compound libraries, will translate discoveries into innovative therapeutic strategies that halt destruction and facilitate recovery of cell dysfunction in diabetes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores